Global cell and gene therapy market
Dublin, May 30, 2022 (GLOBE NEWSWIRE) – The “Global Cell and Gene Therapy Market Report 2022: By Product, By Application, By End User” Report added to ResearchAndMarkets.com Show.
The global market for cells and gene therapy is expected to grow from $6.58 billion in 2021 to $8.57 billion in 2022, at a compound annual growth rate (CAGR) of 30.2%.
The growth is primarily attributable to companies resuming their operations and adapting to the new normal while recovering from the impact of COVID-19, which earlier led to restrictive containment measures including social distancing, remote working and closing of business activities which led to operational challenges.
The market is expected to reach $21.33 billion in 2026 with a compound annual growth rate of 25.6%.
The major players in the cell and gene therapy market are Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio and Fibrocell Science.
The Cell and Gene Therapy market consists of sales of cell and gene therapies by entities (organizations, individual dealers, partnerships) that develop cell and gene therapies. Cellular therapy refers to the transfer of healthy living cells that arose from autologous or allogenic sources, and gene therapy refers to the introduction, removal, or alteration of the genome to treat diseases. The market consists of the revenue that companies developing cell and gene therapy products generate by selling these products.
The main types of products in cell and gene therapy are cell therapy and gene therapy. Gene therapy is a branch of medicine that focuses on modifying the genetic material of cells to achieve a therapeutic effect or to cure disease by repairing or rebuilding damaged genetic material. Various applications include oncology, dermatology, musculoskeletal system and others and include different sectors such as hospitals, ambulatory surgical centers, cancer care centers, wound care centers, among others.
Steady investment and integration in cell and gene therapies have contributed to the growth of the cell and gene therapy (CGT) market. After learning about the potential of the CGT market, 16 out of the 20 largest biopharmaceutical companies by revenue have added CGT products to their portfolio.
For example, Merck invested $109 million in the manufacturing of virus vectors and gene therapy in April 2020. Moreover, 12% of industrial clinical pipeline products and at least 16% of preclinical pipeline products consist of CGT. Steady investment and consolidation of CGT production capacity has increased production capacity and also contributed to market growth.
Limited reimbursement that prevents patients from receiving treatments is expected to limit the growth of cell and gene therapy (CGT) market. In 2019, Trinity Life Sciences, a life sciences solutions provider, conducted research on large national and regional commercial health insurance plans in states United.
It found that the confluence of increasing price, patient volume, and number of CGTs in the market is likely to change the reimbursement model for CGTs and affect payer budgets by 5-10%. Payers understand that financing must be created to manage costs due to the uncertainty surrounding the reimbursement of additional costs. Limited reimbursement processes and uncertain insurance plans prevent patients from receiving high-cost CGT, which is expected to limit market growth.
Chimeric antigen receptor (CAR) T cell therapy is shaping the market for gene cell therapy (CGT). (CAR) T cell therapy is a combination of cell and gene therapy in which T cells are collected from a patient’s blood and genetically modified to produce modified receptors on their surface, known as chimeric antigen receptors (CARs). These modified T cells with special structures (receptors) are reintegrated into the patient.
Then, the T-cell-modifying receptors help target the surface antigen of the cancer cell that ultimately kills the patients’ cancer cells. In 2020, the US Food and Drug Administration approved two Bristol-Myers Squibb CAR-T therapies for the treatment of lymphoma and multiple myeloma, and they are scheduled for release.
Currently, the US Food and Drug Administration has approved CAR-T cell therapy therapies such as Tisagenlecleucel for the treatment of acute B-cell leukemia (ALL) in children and Axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B lymphoma. .
Main topics covered:
1. Executive Summary
2. Cell and Gene Therapy Market Characteristics
3. Cell and Gene Therapy Market Trends and Strategies
4. The effect of COVID-19 on cell and gene therapy
5. Gene therapy market size and growth
5.1 Global Cell and Gene Therapy Market, 2016-2021, US$ Billion
5.1.1. market drivers
5.1.2. Market Restrictions
5.2 Global Cell and Gene Therapy Market Forecast, 2021-2026F, 2031F, billion
5.2.1. market drivers
5.2.2. market restrictions
6. Cell and Gene Therapy Market Segmentation
6.1 Global Cell and Gene Therapy Market Segmentation by Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
6.2 Global Cell and Gene Therapy Market, Segmentation by Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
6.3 Global Cell and Gene Therapy Market, Segmentation by End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $1 Billion
7. Regional and Country Cell Therapy and Gene Therapy Market Analysis
7.1 Global Cell and Gene Therapy Market, Segmented by Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2 Global Cell and Gene Therapy Market, Segmented by Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/1mm93h
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900